Stock Events

Stock Events

Maat Pharma. 

€2.88
37
+€0.02+0.88% 14:50 Today

Statistics

Day High
2.94
Day Low
2.79
52W High
8.18
52W Low
2.3
Volume
6,146
Avg. Volume
-
Mkt Cap
54.28M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29SepExpected
Q4 2025
Next
-1.18
-0.84
-0.51
-0.18
Expected EPS
N/A
Actual EPS
N/A

Financials

-686.58%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
4.52MRevenue
-31.06MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 4RD.STU. It's not an investment recommendation.
TotalEnergies
9
TTE.PA
Air Liquide
7
AI.PA
Lvmh Moet Hennessy Louis Vuitton
6
MC.PA
Airbus
6
AIR.PA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Serve Robotics
SERV
Mkt Cap428.77M
Seres Therapeutics, Inc. focuses on microbiome therapeutics, directly competing in the same space as Maat Pharma with its microbiome restoration therapy products.
Regenxbio
RGNX
Mkt Cap590.16M
REGENXBIO Inc. is involved in gene therapy, which includes treatments that could overlap with Maat Pharma's microbiome-based approaches for certain diseases.
Vertex Pharmaceuticals
VRTX
Mkt Cap138.42B
Vertex Pharmaceuticals Incorporated works on creating new therapies for treating cystic fibrosis and other serious diseases, potentially competing in indications Maat Pharma targets with its microbiome solutions.
Synlogic
SYBX
Mkt Cap8.32M
Synlogic, Inc. is pioneering synthetic biotic medicines, directly competing in the innovative treatment space, including microbiome engineering, similar to Maat Pharma's focus.
Forte Biosciences
FBRX
Mkt Cap1.63B
Fortress Biotech, Inc. is involved in the development of novel pharmaceutical therapies, including areas that might overlap with Maat Pharma's microbiome therapeutic applications.
Evelo Biosciences
EVLO
Mkt Cap1,898
Evelo Biosciences, Inc. focuses on developing microbiome-based therapies, making it a direct competitor in the field of microbiome science like Maat Pharma.
Seres Therapeutics
MCRB
Mkt Cap57.46M
Seres Therapeutics, Inc. (duplicate entry for SERV, focusing on microbiome therapeutics, directly competing with Maat Pharma in microbiome restoration therapy products).
Ardelyx
ARDX
Mkt Cap975.95M
Ardelyx, Inc. develops drugs for gastrointestinal and cardio-renal diseases, areas where microbiome therapies developed by Maat Pharma could be applied.
Galmed Pharmaceuticals
GLMD
Mkt Cap4.14M
Galmed Pharmaceuticals Ltd. works on liver diseases and metabolic disorders, potentially competing with Maat Pharma's microbiome-based treatments for similar conditions.

About

MaaT Pharma SA operates as a clinical-stage biotechnology company, focused on the discovery and advancement of microbiome-based biotherapies, primarily for the treatment of solid cancer tumors. Its development pipeline features MaaT013, which has successfully completed Phase 2 clinical trials for acute graft-versus-host disease (aGVHD) and is also undergoing preclinical evaluation for melanoma. Another therapeutic candidate, MaaT033, is currently in Phase 1b clinical trials, aiming to improve survival outcomes for patients with acute myeloid leukemia (AML) or other liquid malignancies following allogeneic hematopoietic stem cell transplantation. Furthermore, MaaT03X is being developed specifically for solid tumor applications. The company was founded in 2014 and maintains its headquarters in Lyon, France.
Show more...
CEO
Employees
56
Country
France
ISIN
FR0012634822
WKN
000A3C7A5

Listings

STU
DE
4RD.STU
F
DE
4RD.F
MU
DE
4RD.MU
Grey Market
US
MATPF

0 Comments

Share your thoughts

FAQ

What is Maat Pharma. stock price today?▼
The current price of 4RD.STU is €2.88 EUR — it has increased by +0.88% in the past 24 hours. Watch Maat Pharma. stock price performance more closely on the chart.
What is Maat Pharma. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Maat Pharma. stocks are traded under the ticker 4RD.STU.
Is Maat Pharma. stock price growing?▼
4RD.STU stock has fallen by -1.04% compared to the previous week, the month change is a -0.17% fall, over the last year Maat Pharma. has showed a -27.23% decrease.
What is Maat Pharma. market cap?▼
Today Maat Pharma. has the market capitalization of 54.28M
When is the next Maat Pharma. earnings date?▼
Maat Pharma. is going to release the next earnings report on September 29, 2026.
What is Maat Pharma. revenue for the last year?▼
Maat Pharma. revenue for the last year amounts to 4.52M EUR.
What is Maat Pharma. net income for the last year?▼
4RD.STU net income for the last year is -31.06M EUR.
How many employees does Maat Pharma. have?▼
As of September 07, 2026, the company has 56 employees.
In which sector is Maat Pharma. located?▼
Maat Pharma. operates in the Other sector.
When did Maat Pharma. complete a stock split?▼
Maat Pharma. has not had any recent stock splits.